Clicky

Taisho Pharmaceutical Holdings ADR(TAIPY)

Description: Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, and sells over-the-counter (OTC) drugs and prescription pharmaceuticals in Japan and internationally. It operates in two segments, Self-Medication Operation Group and Prescription Pharmaceutical Operation Group. The Self-Medication Operation Group segment offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments, as well as gargles, hand-washing treatments, and face masks; the RiUP series of hair re-growth treatment products; the Taisho Kampo Ichoyaku series of gastrointestinal treatment products; the Colac series of laxative products; and Livita series of food products for specialized health use, as well as engages in the real estate leasing and facility management, and hotel management operations. The Prescription Pharmaceutical Operation Group segment offers ethical drugs, including ZOSYN, an injectable antibiotic; Edirol, an active vitamin D3 osteoporosis agent; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; OZEX and Geninax, quinolone antibacterial; Bonviva, a bisphosphonate antiresorptive agent; Biofermin, a live lactobacillus preparation; Lusefi, a type 2 diabetes mellitus agent; and LOQOA, a transdermal anti-inflammatory analgesic. This segment has various products under development primarily in therapeutic areas, such as central nervous system, infectious, and metabolic diseases, as well as orthopedic disorders. The company also offers raw materials for pharmaceuticals and quasi-drugs; and supplies health foods and skin care products. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is headquartered in Tokyo, Japan.


Keywords: Drugs Food Products Medication Pharmacy Diabetes Skin Care Products Energy Drink Hotel Management Facility Management Osteoporosis Health Food Metabolic Disease Real Estate Leasing Clinical Pharmacology Analgesic Over The Counter Drug Diabetes Mellitus Treatment Products Transdermal Orthopedic Medical Prescription Sinus Viva Prescription Pharmaceuticals Type 2 Diabetes Vitamin D Antibacterial Kampo E Prescription Orthopedic Disorders

Home Page: www.taisho-holdings.co.jp

3-24-1 Takada
Tokyo, 170-8655
Japan
Phone: 81 3 3985 2020


Officers

Name Title
Mr. Akira Uehara CEO & Representative Director
Mr. Ken Uehara MD & Exec. Director
Mr. Shigeru Uehara Exec. VP & Director
Shinichi Tanaka Gen. Mang. of Corp. Communications
Mr. Tetsu Watanabe Exec. Director
Mr. Jun Kuroda Exec. VP & Director
Hideki Iuchi Gen. Mang.
Jinsei Maruyama Corp. Officer
Hisashi Umeoka Director

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE: 36.63
Trailing PE: 21.3123
Price-to-Book MRQ: 0.568
Price-to-Sales TTM: 0.0119
IPO Date:
Fiscal Year End: March
Full Time Employees: 9134
Back to stocks